Q-omics provides the consensus-scored ENTPD7 profile across patient tissues and cancer cell-line models. ENTPD7 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ENTPD7 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, ENTPD7 RNA expression shows 19,772 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where ENTPD7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ENTPD7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ENTPD7 survival associations across molecular data types. ENTPD7 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ENTPD7 RNA expression–survival associations across cancer types. High ENTPD7 expression shows unfavorable associations in ACC, MESO and KICH, but favorable associations in UCS, SCLC and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ENTPD7 RNA expression.
This table summarizes ENTPD7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ENTPD7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ENTPD7 shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRP, LUAD, LUSC and BRCA. The HNSC box plot shows higher ENTPD7 RNA expression in tumor versus normal tissue (log2 FC = +1.629, t-test p < 0.001).
This table shows molecular features associated with ENTPD7 in patient tissues and cancer cell lines. In patient samples, ENTPD7 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ENTPD7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
